QQ客服 官方微博 反馈留言

	Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy (vol 111, pg 492, 2018)
	Zheng, Guirong; Zhao, Ruirui; Xu, Aixiao; Shen, Zhichun; Chen, Xian; Shao, Jingwei
刊名	EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
	2018
卷号	115页码:381-381
ISSN号	0928-0987
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2891229
专题	福州大学
推荐引用方式 GB/T 7714	Zheng, Guirong,Zhao, Ruirui,Xu, Aixiao,et al. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy (vol 111, pg 492, 2018)[J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES,2018,115:381-381.
APA	Zheng, Guirong,Zhao, Ruirui,Xu, Aixiao,Shen, Zhichun,Chen, Xian,&Shao, Jingwei.(2018).Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy (vol 111, pg 492, 2018).EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES,115,381-381.
MLA	Zheng, Guirong,et al."Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy (vol 111, pg 492, 2018)".EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 115(2018):381-381.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。